Back to top

biotechnology: Archive

Zacks Equity Research

New Strong Sell Stocks for August 30th

AMKR, TECH and CIADY have been added to the Zacks Rank #5 (Strong Sell) List on August 30, 2024.

AMKRPositive Net Change TECHPositive Net Change CIADYPositive Net Change

Zacks Equity Research

Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study

NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.

ALNYPositive Net Change NVSPositive Net Change LLYPositive Net Change EXELPositive Net Change

Zacks Equity Research

Addex Stock Soars on Crucial Update From Indivior Research Deal

ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.

JNJNegative Net Change FULCPositive Net Change ADXNPositive Net Change INDVPositive Net Change

Zacks Equity Research

Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review

SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.

ACADPositive Net Change SLNOPositive Net Change FULCPositive Net Change BVSPositive Net Change

Ekta Bagri

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.

REGNPositive Net Change LXRXPositive Net Change GLPGPositive Net Change RYTMPositive Net Change

Nalak Das

2 Must-Buy Medical Stocks With Strong Momentum

Two medical stocks with strong momentum and a favorable Zacks Rank are: DVA, ILMN.

DVANegative Net Change ILMNPositive Net Change

Zacks Equity Research

New Strong Buy Stocks for August 28th

BPMUF, QFIN, CRNC, SN and PINE have been added to the Zacks Rank #1 (Strong Buy) List on August 28, 2024.

SNPositive Net Change BPMUFPositive Net Change QFINPositive Net Change CRNCPositive Net Change PINENegative Net Change

Zacks Equity Research

Roche Obtains Approval For its Rare Blood Disorder Drug in the EU

RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.

AZNPositive Net Change RHHBYNegative Net Change LLYPositive Net Change EXELPositive Net Change

Zacks Equity Research

Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma

REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

REGNPositive Net Change SNYPositive Net Change BAYRYPositive Net Change

Zacks Equity Research

Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids

RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.

ARCTPositive Net Change RYTMPositive Net Change FULCPositive Net Change BVSPositive Net Change

Nalak Das

5 Best Small-Cap Stocks to Benefit From Interest Rate Cuts

We have narrowed our search to five small-cap stocks that have strong momentum. These are FULC, HRTG, SWIM, SHIP and BWAY.

HRTGPositive Net Change SHIPPositive Net Change BWAYNegative Net Change FULCPositive Net Change SWIMNegative Net Change

Zacks Equity Research

Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?

While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.

GSKNegative Net Change GILDPositive Net Change MRUSPositive Net Change

Zacks Equity Research

Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?

Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.

ILMNPositive Net Change

Zacks Equity Research

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.

ARCTPositive Net Change STROPositive Net Change FULCPositive Net Change BVSPositive Net Change

Zacks Equity Research

Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition

Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.

REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYNegative Net Change

Zacks Equity Research

Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug

Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.

LLYPositive Net Change BAYRYPositive Net Change EXELPositive Net Change